Savient to Promote Sobi's Kineret - Analyst Blog


Savient Pharmaceuticals, Inc. ( SVNT ) recently entered into an agreement with Swedish Company Sobi for the co-promotion of Kineret (anakinra) in the US. 

Kineret is approved for the reduction in signs and symptoms along with slowing the progression of structural damage in patients (18 years of age or older) suffering from moderately-to-severely active rheumatoid arthritis.

The patients have failed one or more disease modifying antirheumatic drugs (DMARDs).

The label of Kineret was expanded in Jan 2013 when the US Food and Drug Administration (FDA) approved the drug for the treatment of children and adults suffering from neonatal-onset multisystem inflammatory disease (NOMID). NOMID is a severe form of Cryopyrin-Associated Periodic Syndromes (CAPS).

The agreement provides Savient the exclusive right to co-promote Kineret with Sobi in the US.  Savient will market and promote Kineret from Apr 1, 2013.

Savient believes that Kineret complements the key focus of the company as it works to build upon its existing relationships with rheumatologists and patients while marketing its lead product, Krystexxa.

Krystexxa is approved in the US for the treatment of refractory chronic gout.  Meanwhile, Savient also received marketing authorization for Krystexxa from the EC. 

Savient gained approval from the EC for the treatment of severe debilitating chronic tophaceous gout in adults with erosive joint involvement.

These patients failed to normalize serum uric acid with xanthine oxidase inhibitors at the highest dose.

Currently, Savient Pharmaceuticals carries a Zacks Rank #3 (Hold). Pharma stocks that look better-placed include Array Biopharma ( ARRY ), Agenus Inc ( AGEN ) and Alkermes ( ALKS ), all three carrying a Zacks Rank #2 (Buy).

AGENUS INC (AGEN): Free Stock Analysis Report

ALKERMES INC (ALKS): Free Stock Analysis Report

ARRAY BIOPHARMA (ARRY): Free Stock Analysis Report

SAVIENT PHARM (SVNT): Free Stock Analysis Report

To read this article on click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ, Inc.

This article appears in: Investing , Business , Stocks

Referenced Stocks: AGEN , ALKS , ARRY , CAPS , SVNT

More from

Related Videos



Most Active by Volume

  • $15.38 ▼ 1.09%
  • $110.38 ▲ 0.73%
  • $104.01 ▲ 1.75%
  • $6.3801 ▼ 53.60%
  • $4.25 ▲ 4.94%
  • $15.91 ▲ 7.72%
  • $4.64 ▲ 11.27%
  • $25.47 ▲ 1.11%
As of 10/2/2015, 04:15 PM

Find a Credit Card

Select a credit card product by:
Select an offer:
Data Provided by